SEC-sourced researchBeta
RIGL
RIGEL PHARMACEUTICALS INC
Company comparison ↗
Data passport
- CIK
- 0001034842
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 3, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 116,882,000.0000 | Mar 3, 2026 |
| December 2024 | 179,278,000.0000 | Mar 3, 2026 |
| December 2025 | 294,282,000.0000 | Mar 3, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 294,282,000.0000 | 367,024,000.0000 | 75,655,000.0000 | 513,594,000.0000 | 122,114,000.0000 | Mar 3, 2026 |
| December 2024 | 179,278,000.0000 | 17,485,000.0000 | 31,471,000.0000 | 163,976,000.0000 | 160,688,000.0000 | Mar 3, 2026 |
| December 2023 | 116,882,000.0000 | -25,091,000.0000 | -5,743,000.0000 | — | — | Mar 3, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $294.28M | December 2025 | Mar 3, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $179.28M | December 2024 | Mar 3, 2026 | 10-K |
| Net incomeNetIncomeLoss | $367.02M | December 2025 | Mar 3, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $75.66M | December 2025 | Mar 3, 2026 | 10-K |
| Total assetsAssets | $513.59M | December 2025 | Mar 3, 2026 | 10-K |
| Total liabilitiesLiabilities | $122.11M | December 2025 | Mar 3, 2026 | 10-K |